Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Biogen, which currently sits at a price target of $140. * Reflecting concerns, an analyst from Piper Sandler lowers ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

An analyst from Wells Fargo persists with their Equal-Weight rating on Biogen, maintaining a target price of $140. * Consistent in their evaluation, an analyst from HC Wainwright & Co. keeps a Buy ...